ISIN
GB00BY2Z0H74
Symbol
PRTC

Puretech Health Target price 2026 - Analyst rating & recommendation

Puretech Health Classifications & Recommendation

Buy
86%
Hold
14%

Puretech Health Price Target

Target Price £3.04
Price £1.23
Potential
Number of Estimates 5
5 Analysts have issued a price target Puretech Health 2027 . The average Puretech Health target price is £3.04. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 7 analysts: 6 Analysts recommend Puretech Health to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Puretech Health stock has an average upside potential 2027 of . Most analysts recommend the Puretech Health stock at Purchase.

Sales and Margin forecast 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Million £ 3.49 6.52
3.59% 86.72%
EBITDA Margin -2,043.84% -1,146.70%
25.51% 43.79%
Net Margin -2,356.73% -1,491.68%
312.75% 36.59%

5 Analysts have issued a sales forecast Puretech Health 2026 . The average Puretech Health sales estimate is

£6.5m
unlock
. This is
86.72% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
£10.4m 197.10%
unlock
, the lowest is
£0.0 100.00%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 £3.5m 3.59%
2026
£6.5m 86.72%
unlock
2027
£11.7m 79.72%
unlock
2028
£28.1m 139.78%
unlock

4 Analysts have issued an Puretech Health EBITDA forecast 2026. The average Puretech Health EBITDA estimate is

£-74.7m
unlock
. This is
4.95% lower
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
£-53.2m 25.45%
unlock
, the lowest is
£-113m 57.97%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 £-71.3m 28.18%
2026
£-74.7m 4.95%
unlock
2027
£-58.9m 21.20%
unlock
2028
£-20.4m 65.42%
unlock

EBITDA Margin

2025 -2,043.84% 25.51%
2026
-1,146.70% 43.79%
unlock
2027
-502.80% 56.15%
unlock
2028
-72.51% 85.58%
unlock

4 Puretech Health Analysts have issued a net profit forecast 2026. The average Puretech Health net profit estimate is

£-97.2m
unlock
. This is
18.40% lower
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
£-81.6m 0.75%
unlock
, the lowest is
£-115m 40.02%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 £-82.3m 305.11%
2026
£-97.2m 18.40%
unlock
2027
£-71.2m 26.74%
unlock
2028
£-32.9m 53.85%
unlock

Net Margin

2025 -2,356.73% 312.75%
2026
-1,491.68% 36.59%
unlock
2027
-608.10% 59.23%
unlock
2028
-117.05% 80.75%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share £ -0.34 -0.40
312.50% 17.65%
P/E negative
EV/Sales 15.05

4 Analysts have issued a Puretech Health forecast for earnings per share. The average Puretech Health EPS is

£-0.40
unlock
. This is
17.65% lower
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
£-0.34 0.00%
unlock
, the lowest is
£-0.48 41.18%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 £-0.34 312.50%
2026
£-0.40 17.65%
unlock
2027
£-0.29 27.50%
unlock
2028
£-0.14 51.72%
unlock

P/E ratio

Current -3.56 144.41%
2026
-3.01 15.42%
unlock
2027
-4.11 36.54%
unlock
2028
-8.90 116.55%
unlock

Based on analysts' sales estimates for 2026, the Puretech Health stock is valued at an EV/Sales of

15.05
unlock
and an P/S ratio of
46.13
unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 28.10
2026
15.05 46.45%
unlock
2027
8.37 44.36%
unlock
2028
3.49 58.30%
unlock

P/S ratio

Current
2026
46.13 46.45%
unlock
2027
25.67 44.36%
unlock
2028
10.70 58.30%
unlock

Current Puretech Health Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Peel Hunt Limited
Locked
Locked
Locked Jul 13 2026
Analyst Rating Date
Locked
Peel Hunt Limited:
Locked
Locked
Jul 13 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today